COCP - Cocrystal Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5141
-0.0142 (-2.69%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.5283
Open0.5562
Bid0.5100 x 1000
Ask0.5300 x 1300
Day's Range0.5141 - 0.5639
52 Week Range0.4100 - 5.2800
Volume125,626
Avg. Volume79,601
Market Cap18.071M
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-1.4440
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • GlobeNewswire

    Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

    – Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical.

  • GlobeNewswire

    Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C.

  • GlobeNewswire

    Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

    BOTHELL, WA, Nov. 11, 2019 (GLOBE NEWSWIRE) --  Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, presented at the AASLD 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA, new data in a poster demonstrating positive data from its triple regimen, U.S. Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals. The poster titled, “Immune Cell Phenotypes Associated with Successful Response to 2 Weeks of a Novel Non-Nucleoside Inhibitor CDI-31244 Concurrent with 6 Weeks of Sofosbuvir/Velpatasvir in Subjects with Chronic Hepatitis C Genotype 1 Infection,” was presented by Joel Chua, MD, Assistant Professor of Medicine of the Institute of Human Virology at the University of Maryland School of Medicine and Principal Investigator of the U.S. Phase 2a trial, on Sunday November 10, 2019 and is available on the Company’s website here.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING

    COCRYSTAL PHARMA, INC. (COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.0 million before deducting underwriting discounts and expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes. The Company also granted the underwriters a 45-day option to purchase up to 529,411 additional shares of common stock to cover over-allotments, if any, at the public offering price.

  • GlobeNewswire

    COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

    COCRYSTAL PHARMA, INC. (COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for operations, including payment of general and administrative expenses and other working capital and general corporate purposes.

  • GlobeNewswire

    Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that its poster demonstrating positive data from its triple regimen, U.S. Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultra-short treatment of HCV infected individuals was selected for presentation at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA. “We are pleased to be presenting this positive data at the AASLD 2019 meeting.

  • Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO?
    Simply Wall St.

    Is Cocrystal Pharma, Inc. (NASDAQ:COCP) Overpaying Its CEO?

    In 2016 Gary Wilcox was appointed CEO of Cocrystal Pharma, Inc. (NASDAQ:COCP). This report will, first, examine the...

  • GlobeNewswire

    Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, presented positive data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses (“HCV2019”) Conference being held on October 5-8, 2019 in Seoul, South Korea. As part of his poster presentation, Dr. Lee provided an overview of the Company's proprietary structure-based drug discovery technology which has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective non-nucleoside inhibitor (NNI) that is active against all HCV genotypes (1-6) with low level cytotoxicity in multiple cell types.

  • GlobeNewswire

    Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, will present data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses (“HCV2019”) Conference being held October 5-8, 2019 in Seoul, South Korea. The Company's proprietary structure-based drug discovery technology has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective NNI that is active against all HCV genotypes (1-6) with low level cytotoxicity in multiple cell types.

  • GlobeNewswire

    Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that James Martin, Chief Financial Officer of Cocrystal will present a corporate overview at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 1:45 PM ET in New York, NY. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

  • Those Who Purchased Cocrystal Pharma (NASDAQ:COCP) Shares Three Years Ago Have A 87% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Cocrystal Pharma (NASDAQ:COCP) Shares Three Years Ago Have A 87% Loss To Show For It

    It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...

  • GlobeNewswire

    Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, presented positive preclinical data of CC-42344 at the ISIRV: Options X for the Control of Influenza Conference being held August 28-September 1, 2019 in Singapore. As part of his oral presentation, Dr. Lee provided an overview of the Company’s distinct class of PB2 inhibitors developed utilizing its structure-based technology.

  • GlobeNewswire

    Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it will present preclinical data of CC-42344 at the ISIRV: Options X for the Control of Influenza Conference being held August 28-September 1, 2019 in Singapore. CC-42344 is the Company’s novel, potent, broad spectrum anti-influenza preclinical lead molecule which targets the cap-binding PB2 domain, and is active against a panel of seasonal, pandemic, and Tamiflu-resistant influenza A strains.

  • GlobeNewswire

    Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today its financial results for the quarter ended June 30, 2019 and provided a corporate update. “We remain focused on advancing our hepatitis C clinical development program as well as driving forward our earlier-stage influenza and norovirus programs,” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. In addition, there have been recent industry research and development collaborations and licensing agreements for platform technologies, and we continue to explore similar opportunities with our platform,” added Dr. Wilcox.

  • Cocrystal Pharma, Inc. (NASDAQ:COCP): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    Cocrystal Pharma, Inc. (NASDAQ:COCP): What Does Its Beta Value Mean For Your Portfolio?

    If you own shares in Cocrystal Pharma, Inc. (NASDAQ:COCP) then it's worth thinking about how it contributes to the...

  • Do Insiders Own Shares In Cocrystal Pharma, Inc. (NASDAQ:COCP)?
    Simply Wall St.

    Do Insiders Own Shares In Cocrystal Pharma, Inc. (NASDAQ:COCP)?

    A look at the shareholders of Cocrystal Pharma, Inc. (NASDAQ:COCP) can tell us which group is most powerful...

  • GlobeNewswire

    Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

    Cocrystal Pharma, Inc. (COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has commenced patient enrollment in its Phase 2a study in Hong Kong SAR, China. The Phase 2a open-label study being conducted at Humanity & Health Research Centre, Humanity and Health Medical Group, in Hong Kong will evaluate the safety, tolerability and preliminary efficacy of Cocrystal’s CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhibitor, for the treatment of hepatitis C (HepC).

  • GlobeNewswire

    Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update

    – Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 –.

  • GlobeNewswire

    Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook

    – Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to.

  • GlobeNewswire

    Cocrystal Pharma Announces Closing of Private Placement

    Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it had entered into binding agreements to sell 1,602,283 shares of the Company's common stock and will receive gross proceeds of $4,181,958 in a private placement offering. The purchasers in the private placement consisted of three qualified, fundamental healthcare-focused institutional investors that are existing stockholders of Cocrystal. Cocrystal intends to use the net proceeds from the offering to fund research and development activities, including the clinical advancement of its novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses, and for working capital and other general corporate purposes.

  • GlobeNewswire

    Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

    - Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as.

  • Business Wire

    Robbins Arroyo LLP: Shareholder Lawsuit Says Cocrystal Pharma, Inc. (COCP) Misled Shareholders

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cocrystal Pharma, Inc. (formerly known as BioZone Pharmaceuticals, Inc.) (COCP) filed a shareholder lawsuit against the company's officers and directors for alleged breaches of fiduciary duties, unjust enrichment, waste of corporate assets, and violations of the Securities Exchange Act of 1934. According to the complaint, BioZone officials schemed to artificially inflate the company's stock price and sell their shares at a significant profit. After reaping massive profits, they carried out another reverse merger through which BioZone became Cocrystal Pharma and solicited Cocrystal stockholder votes for director re-election, all while hiding the company's liability for the pump-and-dump scheme.

  • GlobeNewswire

    Cocrystal Announces Board Changes

    Cocrystal Pharma, Inc., a biotechnology company with a proprietary technology platform focused on developing medicines to treat viral diseases, today announced changes to its board of directors. Dr. Raymond F Schinazi, who has served as chairman or co-chairman of Cocrystal’s board of directors since November 2014, has elected to retire from the board on February 1, 2019. Pending compliance approval from his academic affiliations, he will become a special advisor to the CEO and also serve on the scientific advisory board.

  • ACCESSWIRE

    4 Pharma Stocks Raising Eyebrows (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / With the new year only a few days old, the pharmaceutical industry is already buzzing with the excitement surrounding companies who are taking innovative approaches to create a variety of effective treatment options for patients in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyepoint Pharmaceuticals, Inc (NASDAQ: EYPT), Cocrystal Pharma Inc (NASDAQ: COCP), and Fred's, Inc (NASDAQ: FRED) are 4 pharma stocks to keep tabs on as the industry moves toward the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made several key announcements in the past few months to show investors, as well as members of its 100,000 patient ecosystem, that the Company is committed to the advancement of this goal.